Proteasis Evaluation in COPD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

134 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-10-18

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to evaluate kallikreins and its substrate, CCN, in COPD patients. Kallikreins are a subgroup of serine proteases, enzymes which are able to cleave peptide bonds in proteins. Kallicrein profile is unkonwn in COPD. The investigators will assess Kallikrein 1 to 15 and CCN 1 to 6 in sputum of patients. Three groups of patients will be included: Healthy smoker subjects, stable COPD patients and COPD patients with acute exacerbation. Kallicrein levels in sputum will be compared in these groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Experimentation With Screening for Bronchopulmonary Cancer and Primary Cardiovascular Prevention, Early Management of COPD and an Offer Exempted From Smoking Cessation

NCT05440123

the Rate of Participation in Screening for PBC

NOT_YET_RECRUITING

Development of a Noninvasive Method of Evaluation of Pulmonary Inflammation in the Condensates of Exhaled Air

NCT00356629

Bronchopulmonary Ignition Condensate of Exhaled Air Mucoviscidosis +1 more

TERMINATED

Protein, Sarcopenic Obesity, and COPD

NCT06735573

Sarcopenic Obesity Chronic Obstructive Pulmonary Diseases

NOT_YET_RECRUITING

Feasibility of Proteomics in Chronic Lung Disease With Sarcopenia

NCT06312774

Sarcopenia Chronic Lung Disease

NOT_YET_RECRUITING

Biomarkers of Chronic Obstructive Pulmonary Disease

NCT04963023

COPD Asthma-COPD Overlap Syndrome Asthma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Smoker with tobacco consumption of 20 pack/year
* Normal lung function tests

* Smoker with tobacco consumption of 20 pack/year
* FEV1/FVC\<70% on lung function tests
* no hospitalisation for exacerbation during 3 months before inclusion

* Smoker with tobacco consumption of 20 pack/year
* worsening of pulmonary symptoms
* FEV1/FVC\<70% on lung function tests could be obtain before or 3 months after exacerbation

Exclusion Criteria

* diagnosis of lung disease during the study
* Asthma
* Lung cancer
* Pregnant and lactating women

* Asthma
* Lung cancer
* Pregnant and lactating women

* Asthma
* Lung cancer
* Pregnant and lactating women

Minimum Eligible Age

50 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes